News & Comment

Filter By:

  • Gold-standard cancer data management is pivotal to enable precision medicine for European citizens. Achieving this goal relies on key elements: adopting standardized data formats, ensuring robust data privacy, educating professionals about the infrastructure’s benefits and leveraging cutting-edge technologies to transform cancer care.

    • Macha Nikolski
    • Eivind Hovig
    • Gary Saunders
    Comment
  • Drug regulatory agencies in the USA and Europe have mechanisms to provide patients faster access to novel treatments, expecting that follow-up trials will confirm clinically meaningful results. However, some early approvals are subsequently withdrawn. Here we discuss the insights gained from withdrawn accelerated approvals for oncologic agents in the past decade.

    • George S. Mellgard
    • Tito Fojo
    • Susan E. Bates
    Comment
  • Anirban Maitra obtained his medical degree from the All India Institute of Medical Sciences, New Delhi, in 1996; this was followed by residency and fellowships in pathology at the University of Texas Southwestern Medical Center, Dallas, and Johns Hopkins University School of Medicine, Baltimore. From 2002 to 2013, he served as faculty in the departments of pathology and oncology at Johns Hopkins, before being recruited to the MD Anderson Cancer Center as Professor of Pathology and Translational Molecular Pathology and Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research.

    • Anirban Maitra
    Turning Points
  • Rebecca Fitzgerald completed her medical degree at the University of Cambridge, followed by doctoral research at Stanford University, and then postdoctoral research alongside specialist training in gastroenterology at Barts and the London Hospitals. She started her own independent group the MRC Cancer Unit in 2001 with an honorary gastroenterology consultant position at Addenbrooke’s Hospital. In 2014, she was elected to chair in cancer prevention, and in 2022 inaugural director of the department of oncology at the Early Cancer Institute, University of Cambridge.

    • Rebecca Fitzgerald
    Turning Points
  • We bid farewell to the past year with a set of specially commissioned commentaries, news articles and a selection of highlights from the cancer research literature.

    Editorial
  • Bispecific T cell engagers and antibody–drug conjugates took center stage in a year that also brought several new kinds of small-molecule therapies.

    • Elie Dolgin
    News Feature
  • From halted healthcare services and corrupted code to stolen personal data held for ransom, cyberwarfare knows no boundaries. Healthcare providers are now facing unprecedented challenges from hackers, with uncertain consequences to patients with cancer.

    • Karl Gruber
    News Feature
  • Real-world data (RWD) and real-world evidence (RWE) from heterogeneous data sources has the potential to transform oncology research, especially when coupled with artificial intelligence (AI). We discuss the issues involved in primary data capture and post-hoc AI analysis and propose using AI to support the capture of primary RWD.

    • Piers Mahon
    • Geoff Hall
    • Giovanni Tonon
    Comment